Synaptogenix Inc (SNPX)

[SF Wolf]

If, as I believe, that Neurotrope will be the first company in the history of AD research to report a treatment that actually works it is going to be the industry leader and dominate news on Alzheimer’s in the popular press. The term “media frenzy” comes to mind.

But more importantly, the Trump administration has indicated it wants less oversight and more fast track approval of promising drugs and it might turn out that with positive Phase2b results Bryostatin will be an early candidate for some kind of new FDA expedited approval process.

The potential societal and fiscal benefits will likely bring tremendous pressure on the FDA to act if Neurotrope is successful.

Alzheimer’s is a major drain on Medicare, Medicaid, and Social Security Disability benefit programs. An effective treatment will change the math on all of those programs saving families and governments all over the world untold billions.